INCLISIRAN
Body System:
Manner of administration:Injection
Restriction (Streamlined authority code: 16320)
Indication: Familial heterozygous hypercholesterolaemia
Treatment phase: Continuing treatment with this drug or switching treatment from a monoclonal antibody
inhibiting proprotein coverase subtilisin kexin type 9 (PSCK9) for this PBS indication
Restriction (Streamlined authority code: 16356)
Indication: Non-familial hypercholesterolaemia
Treatment phase: Continuing treatment with this drug or switching treatment from a monoclonal antibody
inhibiting proprotein coverase subtilisin kexin type 9 (PSCK9) for this PBS indication
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 0 | DPMQ: $1,849.80 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Leqvio | |||||
Body System:
Manner of administration:Injection
Restriction (Streamlined authority code: 16295)
Indication: Familial heterozygous hypercholesterolaemia
Treatment phase: Initial treatment
Restriction (Streamlined authority code: 16331)
Indication: Non-familial hypercholesterolaemia
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 1 | DPMQ: $1,849.80 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Leqvio | |||||